Zoetis Inc. (NYSE:ZTS) Shares Sold by AAFMAA Wealth Management & Trust LLC

AAFMAA Wealth Management & Trust LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 67.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,891 shares of the company’s stock after selling 20,250 shares during the period. AAFMAA Wealth Management & Trust LLC’s holdings in Zoetis were worth $1,933,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Webster Bank N. A. grew its holdings in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Quarry LP lifted its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. LRI Investments LLC purchased a new stake in Zoetis in the 1st quarter valued at approximately $43,000. Hazlett Burt & Watson Inc. lifted its stake in Zoetis by 60.7% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at approximately $49,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ZTS shares. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Up 1.1 %

Shares of Zoetis stock opened at $194.45 on Thursday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market cap of $88.10 billion, a PE ratio of 38.05, a P/E/G ratio of 2.99 and a beta of 0.89. The business’s fifty day moving average is $188.76 and its two-hundred day moving average is $176.70. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.41 EPS. Analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.89%. Zoetis’s payout ratio is 33.86%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.